$ALLR News

Allarity Therapeutics Secures CLIA For In-House Lab

Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic

Allarity Therapeutics, Inc. (ALLR) Shareholder/Analyst Call Prepared Remarks Transcript

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congress, June 17–19

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Says API Manufacturing Campaign For Stenoparib Is Progressing In Line With Planned Timeline For Completion No Later Than Q3 Of 2026 At CDMO

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Says USPTO Issues Notice Of Allowance For Patent Application Covering DRP Companion Diagnostic Specific To Stenoparib

Allarity Therapeutics Says USPTO Issues Notice Of Allowance For Patent Application Covering DRP Companion Diagnostic Specific To Stenoparib

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K

Allarity closes $20M financing for stenoparib advancement